Bristol Myers Squibb in an all-cash deal at $5 per share, with the merger set to close in Q2 2025. Despite Abecma generating $242 million in U.S. sales, 2seventy still booked a $3.3 million loss from ...

Shares of Bristol Myers Squibb Co. slid 3.05% to $59.19 Tuesday, on what proved to be an all-around favorable trading session ...

"It’s as much of the marquee high-value transactions as it is the aggregation of what we call our bread and butter, and it’s that combination that ends up being magical for us in the end,” said CEO ...

"It’s as much of the marquee high-value transactions as it is the aggregation of what we call our bread and butter, and it’s ...

Bearish flow noted in Bristol Myers ( BMY) Squibb with 13,765 puts trading, or 2x expected. Most active are Apr-25 60 puts and 4/4 weekly 60 puts, with total volume in those strikes near 8,600 ...

BMY has enjoyed robust capital appreciation over the past few months, significantly aided by the ongoing market rotation to ...

After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

A record number of single-premium pension risk transfer (PRT) contracts were sold in 2024, driven by strong sales in the ...

The recent approvals and robust pipeline activity are expected to fuel the market of molecular glues in the 7MM during the forecast period 2025-2034 due to factors like improved diagnosis, treatment ...

Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating ...